REG - Haleon PLC - Transactions in Own Shares

HALEONAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260330:nRSd5243Ya&default-theme=true

RNS Number : 5243Y  Haleon PLC  30 March 2026

 

Haleon plc: Aggregated information - transactions in own shares

 

30 March 2026: Haleon plc (the "Company" or "Haleon") today announces the
purchase of 8,939,706 ordinary shares of £0.01 each in the Company (the
"Shares") for cancellation under its share buyback programme announced on 12
March 2026.

 

                                                    London Stock Exchange  CBOE (UK)/BXE  CBOE (UK)/CXE  Aquis
 Date of purchase:                                  23 March 2026
 Number of Shares purchased:                        907,436                616,421        676,143        -
 Highest price paid per Share (p):                  373.0000               372.8000       373.0000       -
 Lowest price paid per Share (p):                   366.1000               366.1000       366.1000       -
 Volume weighted average price paid per Share (p):  369.4258               369.3119       369.2976       -
 Date of purchase:                                  24 March 2026
 Number of Shares purchased:                        1,249,993              701,254        795,863        -
 Highest price paid per Share (p):                  367.5000               367.4000       367.5000       -
 Lowest price paid per Share (p):                   353.7000               354.5000       354.2000       -
 Volume weighted average price paid per Share (p):  360.6000               360.5385       362.0296       -
 Date of purchase:                                  25 March 2026
 Number of Shares purchased:                        695,658                362,573        541,769        -
 Highest price paid per Share (p):                  365.0000               364.4000       365.0000       -
 Lowest price paid per Share (p):                   358.0000               358.0000       358.0000       -
 Volume weighted average price paid per Share (p):  360.7481               360.6592       360.7231       -
 Date of purchase:                                  26 March 2026
 Number of Shares purchased:                        482,718                281,517        329,302        -
 Highest price paid per Share (p):                  365.7000               365.7000       365.7000       -
 Lowest price paid per Share (p):                   361.4000               361.3000       361.3000       -
 Volume weighted average price paid per Share (p):  363.8089               363.8804       363.9063       -
 Date of purchase:                                  27 March 2026
 Number of Shares purchased:                        577,607                344,828        376,624        -
 Highest price paid per Share (p):                  367.2000               367.2000       367.2000       -
 Lowest price paid per Share (p):                   361.2000               361.2000       361.2000       -
 Volume weighted average price paid per Share (p):  364.5493               364.7299       364.6569       -

 

Following the settlement of the above, the Company's registered share capital
is 8,932,831,335 ordinary shares of £0.01 each, of which 12,548,735 are
held as treasury shares. Therefore, the number of ordinary shares with voting
rights is 8,920,282,600 and this figure may be used by shareholders to
determine if they are required to notify their interest, or a change to their
interest, in Haleon under the FCA's Disclosure Guidance and Transparency
Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it
applies in the UK (the Market Abuse Regulation), a full breakdown of the
individual trades is available at the link below:

 

http://www.rns-pdf.londonstockexchange.com/rns/5243Y_1-2026-3-27.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/5243Y_1-2026-3-27.pdf)

 

This announcement does not constitute, or form part of, an offer or any
solicitation of an offer for securities in any jurisdiction.

 

This announcement and individual trade breakdown will also be available on the
Company's website at: www.haleon.com/investors
(http://www.haleon.com/investors) .

 

 Enquiries

 Investors                                                                       Media

 Jo Russell                              +44 7787 392441                         Zoë Bird                             +44 7736 746167
 Rakesh Patel                            +44 7552 484646                         Victoria Durman                      +44 7894 505730
 Email: investor-relations@haleon.com (mailto:investor-relations@haleon.com)     Email: corporate.media@haleon.com (mailto:corporate.media@haleon.com)

 

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better
everyday health. Our people, our brands, our research, our investment and our
innovation are aimed at improving the everyday health of consumers. Our
product portfolio spans six major categories - Oral Health, Vitamins, Minerals
and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and
Therapeutic Skin Health and Other. Our superior brands - such as Advil,
Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and
Voltaren - are trusted by more than one billion consumers and are recommended
by health professionals around the world.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSBRGDXXSDDGLR



            Copyright 2019 Regulatory News Service, all rights reserved